IDH1 Mutation (R132H) Immunostain, Technical Component Only
Use
The IDH1 R132H mutation is frequently observed in World Health Organization grade II and III gliomas, and it is recognized as an early event in gliomagenesis. It can serve as a diagnostic marker to differentiate infiltrating gliomas from gliosis and is also used as a prognostic marker in gliomas and secondary glioblastoma multiforme. The IDH1 R132H antibody specifically binds to the mutated IDH1 protein but does not bind to the wild-type protein, showing strong cytoplasmic and weaker nuclear staining in tumor cells with the R132H-mutated peptide.
Special Instructions
Not provided.
Limitations
Age and environmental factors can affect the immunoreactivity of paraffin sections and glass slides. paraffin sections should ideally be cut within six weeks to ensure optimal immunoreactivity. Additionally, the charge and surface chemistry of glass slides can impact staining results, so care should be taken to minimize exposure to humidity and heat. The test does not include a pathologist's interpretation; if an interpretation is needed, PATHC / Pathology Consultation should be ordered separately.
FDA ApprovedNew York Approved
Methodology
Immunoassay (IHC)
Biomarkers
IDH1 R132H
Protein
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Immunostain Technical Only Envelope
Collection Instructions
Formalin-fixed, paraffin-embedded tissue block or 2 unstained glass slides per test.
Causes for Rejection
Wet/frozen tissue, cytology smears, nonformalin fixed tissue, nonparaffin embedded tissue, noncharged slides, inappropriate slide types.